Screening of a heptamer-type sgRNA library for potential therapeutic agents against hematological malignancies

Leukemia Research

Volumn 38, Issue 7, 2014, Pages 808-815

  Takahashi, Masayuki ^a   Elbarbary, Reyad A ^a   Watanabe, Norihiro ^a,b   Goto, Atsushi ^a   Kamiya, Daichi ^a   Watabe, Yoshihiro ^a   Uchiyama, Takayoshi ^b   Narita, Miwako ^b   Takahashi, Masuhiro ^b   Takahashi, Yoshiaki ^b   Ishihara, Noriko ^c   Miyazawa, Tatsuya ^d   Yoshida, Tetsuo ^d   Kawano, Mitsuoki ^a,e   Tamura, Masato ^e   Nashimoto, Masayuki ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c Department of Clinical Pathology Saiseikai Niigata Daini Hospital   (Japan)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Leukemia; Multiple myeloma; RNA therapy; SgRNA; TRUE gene silencing

Indexed keywords

RNA; SMALL GUIDE RNA 156; SMALL GUIDE RNA 20; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEMATOLOGIC MALIGNANCY; HL 60 CELL LINE; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MOUSE; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA LIBRARY; RNA STRUCTURE; RNA SYNTHESIS;

LEUKEMIA; MULTIPLE MYELOMA; RNA THERAPY; SGRNA; TRNASE Z(L); TRUE GENE SILENCING;

ANIMALS; CELL LINE, TUMOR; ENDORIBONUCLEASES; GENE LIBRARY; GENE SILENCING; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, GUIDE;

EID: 84902075002     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.021     Document Type: Article

References (39)

1. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
2. Gambacorti-Passerini C., Antolini L., Mahon F.X., Guilhot F., Deininger M., Fava C., et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011, 103:553-561.
3. Jakubowiak A.J., Dytfeld D., Griffith K.A., Lebovic D., Vesole D.H., Jagannath S., et al. Phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012, 120:1801-1809.
4. Chapman M.A., Lawrence M.S., Keats J.J., Cibulskis K., Sougnez C., Schinzel A.C., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
5. Stephens P.J., Greenman C.D., Fu B., Yang F., Bignell G.R., Mudie L.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
6. Magrangeas F., Avet-Loiseau H., Munshi N.C., Minvielle S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 2011, 118:675-678.
7. Egan J.B., Shi C.X., Tembe W., Christoforides A., Kurdoglu A., Sinari S., et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012, 120:1060-1066.
8. Koch C. Modular biological complexity. Science 2012, 337:531-532.
9. Yates L.A., Norbury C.J., Gilbert R.J. The long and short of microRNA. Cell 2013, 153:516-519.
10. Landais S., Landry S., Legault P., Rassart E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 2007, 67:5699-5707.
11. Pichiorri F., Suh S.S., Ladetto M., Kuehl M., Palumbo T., Drandi D., et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. PNAS 2008, 105:12885-12890.
12. L through 5'-half-tRNA. PLoS ONE 2009, 4:e5908.
13. L can downregulate gene expression through miRNA. FEBS Lett 2009, 583:3241-3246.
14. Scherer L., Rossi J.J. Therapeutic potential of RNA-mediated control of gene expression: options and designs. RNA and the regulation of gene expression: a hidden layer of complexity 2008, 201-226. Caister Academic Press, Inc., Norfolk. K.V. Morris (Ed.).
15. Nashimoto M. Conversion of mammalian tRNA 3' processing endoribonuclease to four-base-recognizing RNA cutters. Nucleic Acids Res 1995, 23:3642-3647.
16. Nashimoto M. Specific cleavage of target RNAs from HIV-1 with 5' half tRNA by mammalian tRNA 3' processing endoribonuclease. RNA 1996, 2:2523-2524.
17. Nashimoto M., Geary S., Tamura M., Kasper R. RNA heptamers that directs RNA cleavage by mammalian tRNA 3' processing endoribonuclease. Nucleic Acids Res 1998, 26:2565-2571.
18. Nashimoto M. Anomalous RNA substrates for mammalian tRNA 3' processing endoribonuclease. FEBS Lett 2000, 472:179-186.
19. Takaku H., Minagawa A., Masamichi T., Nashimoto M. A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoriobonuclease. Nucleic Acids Res 2003, 31:2272-2278.
20. Takaku H., Minagawa A., Takagi M., Nashimoto M. The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity. Nucleic Acids Res 2004, 32:4429-4438.
21. Takaku H., Minagawa A., Takagi M., Nashimoto M. A novel four-base-recognizing RNA cutter that can remove the single 3' terminal nucleotides from RNA molecules. Nucleic Acids Res 2004, 32:e91.
22. Shibata H.S., Takaku H., Takagi M., Nashimoto M. The T loop structure is dispensable for substrate recognition by tRNase ZL. J Biol Chem 2005, 280:22326-22334.
23. Tamura M., Nashimoto C., Miyake N., Daikuhara Y., Ochi K., Nashimoto M. Intracellular mRNA cleavage by 3' tRNase under the direction of 2'-O-methyl RNA heptamers. Nucleic Acids Res 2003, 31:4354-4360.
24. Habu Y., Miyano-Kurosaki N., Kitano M., Endo Y., Yukita M., Ohira S., et al. Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL. Nucleic Acids Res 2005, 33:235-243.
25. L under the direction of small guide RNA. Gene Ther 2007, 14:78-85.
26. Elbarbary R.A., Takaku H., Tamura M., Nashimoto M. Inhibition of vascular endothelial growth factor expression by TRUE gene silencing. Biochem Biophys Res Commun 2009, 379:924-927.
27. Sano T., Takahashi M., Nozaki T., Takahashi Y., Tamura M., Nashimoto M. Expanding the utility of heptamer-type sgRNA for TRUE gene silencing. Biochem Biophys Res Commun 2011, 416:427-432.
28. Takahashi M., Elbarbary R.A., Abe M., Sato M., Yoshida T., Yamada Y., et al. Elimination of specific miRNAs by naked 14-nt sgRNAs. PLoS ONE 2012, 7:e38496.
29. Takahashi M., Elbarbary R.A., Nakashima A., Abe M., Watanabe N., Narita M., et al. A naked RNA heptamer targeting the human Bcl-2 mRNA induces apoptosis of HL60 leukemia cells. Cancer Lett 2013, 328:362-368.
30. Watanabe N., Narita M., Yamahira A., Taniguchi T., Furukawa T., Yoshida T., et al. Induction of apoptosis of leukemic cells by TRUE gene silencing using small guide RNAs targeting the WT1 mRNA. Leuk Res 2013, 37:580-585.
31. Loke S.L., Stein C.A., Zhang X.H., Mori K., Nakanishi M., Subasinghe C., et al. Characterization of oligonucleotide transport into living cells. PNAS 1989, 86:3474-3478.
32. Gallagher R., Collins S., Trujillo J., McCredie K., Ahearn M., Tsai S., et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979, 54:713-733.
33. Togawa A., Inoue N., Miyamoto K., Hyodo H., Namba M. Establishment and characterization of a human myeloma cell line (KMM-1). Int J Cancer 1982, 29:495-500.
34. Matsuoka Y., Moore G.E., Yagi Y., Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 1967, 125:1246-1250.
35. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
36. Scherer W.F., Syverton J.T., Gey G.O. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 1953, 97:695-710.
37. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36:59-74.
38. Nakano K., Yamaoka K., Hanami K., Saito K., Sasaguri Y., Yanagihara N., et al. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 2011, 186:3745-3752.
39. Cheetham S.W., Gruhl F., Mattick J.S., Dinger M.E. Long noncoding RNAs and the genetics of cancer. Br J Cancer 2013, 108:2419-2425.